Physician
Ame Medical Group INC
Ame Medical Group INC was paid $5.39M by Medicaid between Jan 2018 and Dec 2024, across 62 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 49% of everything it billed.
33Billing provider infoAME MEDICAL GROUP INC
DOWNEY, CA 90242
DOWNEY, CA 90242
33aNPI1861711863assigned 05/31/2010
33bProvider typeFamily Medicine Physician
28Total paid$5.39M
24GClaims590,522
24DCodes billed62
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in California
Rank by total paid#68 of 2,511
Median peer was paid$13K
This provider vs. median420×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 51,561 | $418K | |
| 2019 | 106,891 | $961K | |
| 2020 | 64,956 | $547K | |
| 2021 | 67,753 | $668K | |
| 2022 | 103,583 | $973K | |
| 2023 | 116,055 | $1.18M | |
| 2024incomplete | 79,723 | $645K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 49% | 84,581 | 77,945 | $2.66M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 23% | 54,978 | 47,635 | $1.21M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 9.6% | 13,004 | 12,351 | $519K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 4.4% | 5,191 | 4,633 | $235K |
| 3008F | 2.2% | 139,097 | 127,558 | $120K | |
| 3074F | 2.2% | 94,745 | 88,299 | $119K | |
| 99243 | 1.6% | 5,518 | 5,170 | $86K | |
| 99201 | 1.3% | 1,620 | 1,557 | $68K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.1% | 893 | 845 | $58K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.1% | 3,279 | 2,627 | $57K |
| 3078F | <1% | 73,553 | 69,370 | $50K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,741 | 1,615 | $36K |
50 more codes
| 3079F | <1% | 39,112 | $25K | |
| 3075F | <1% | 16,731 | $18K | |
| 99385 | <1% | 745 | $17K | |
| S9083 | Global fee urgent care centers | <1% | 370 | $14K |
| 99386 | <1% | 567 | $10K | |
| 81002 | <1% | 13,923 | $10K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 581 | $9K |
| 3077F | <1% | 11,647 | $9K | |
| 3080F | <1% | 10,706 | $8K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 466 | $7K |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 75 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,067 | $5K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,254 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 124 | $3K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 109 | $2K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 1,552 | $2K |
| 99205 | Prolong outpt/office vis | <1% | 293 | $1K |
| 72100 | <1% | 516 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 304 | $1K |
| 73562 | <1% | 709 | $1K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 97 | $1K |
| 73610 | <1% | 496 | $1K | |
| 93000 | <1% | 136 | $975.18 | |
| 73630 | <1% | 499 | $942.57 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,170 | $908.39 |
| 82962 | <1% | 1,797 | $855.05 | |
| 81025 | <1% | 690 | $839.70 | |
| 69210 | <1% | 92 | $638.05 | |
| 69209 | <1% | 199 | $626.65 | |
| 85018 | <1% | 1,210 | $581.47 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 79 | $463.64 |
| 97802 | <1% | 162 | $428.36 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,757 | $394.93 |
| 72040 | <1% | 165 | $369.35 | |
| 73130 | <1% | 172 | $293.36 | |
| 73030 | <1% | 177 | $229.59 | |
| 73140 | <1% | 103 | $165.05 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 30 | $155.54 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 28 | $118.72 |
| 88141 | <1% | 109 | $115.83 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 14 | $85.12 |
| 73110 | <1% | 48 | $77.37 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 29 | $62.22 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 85 | $56.44 |
| 72072 | <1% | 13 | $31.67 | |
| 72120 | <1% | 25 | $28.13 | |
| 71045 | Radiologic examination, chest; single view | <1% | 14 | $15.82 |
| 86580 | <1% | 14 | $13.33 | |
| 99000 | <1% | 22 | $3.59 | |
| 99173 | <1% | 39 | $3.58 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNARKAR, SUNIL (CEO)